Nifty
Sensex
:
:
10705.75
36235.35
-93.90 (-0.87%)
-93.66 (-0.26%)

Pharmaceuticals & Drugs - Global

Rating :
67/99  (View)

BSE: 531633 | NSE: LINCOLN

162.80
-3.25 (-1.96%)
08-Jul-2020 | 3:55PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  165.50
  •  169.45
  •  162.00
  •  166.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  23403
  •  38.10
  •  218.80
  •  85.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 326.40
  • 6.87
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 352.43
  • 0.92%
  • 1.09

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.36%
  • 14.30%
  • 45.48%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 7.86%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.28
  • 9.60
  • 5.08

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.94
  • 21.16
  • 7.29

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.24
  • 25.86
  • 19.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.45
  • 11.55
  • 8.98

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.40
  • 1.81
  • 1.59

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.86
  • 7.45
  • 7.04

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
0
79
-100%
99
84
17%
113
103
10%
97
100
-3%
Expenses
0
68
-100%
85
71
20%
88
84
5%
78
77
2%
EBITDA
0
11
-100%
13
14
-3%
25
19
29%
19
23
-18%
EBIDTM
0%
14%
13%
16%
22%
19%
20%
23%
Other Income
0
-1
-
3
0
700%
3
4
-43%
1
2
-44%
Interest
0
1
-100%
1
1
90%
1
2
-67%
1
1
-51%
Depreciation
0
2
-100%
2
2
-3%
2
2
17%
2
2
17%
PBT
0
8
-100%
13
11
15%
25
20
23%
18
23
-21%
Tax
0
-1
-
2
2
-6%
6
5
13%
5
7
-22%
PAT
0
8
-100%
11
9
19%
19
15
26%
13
16
-21%
PATM
0%
11%
11%
11%
17%
15%
13%
16%
EPS
0.00
4.24
-100%
5.46
4.57
19%
9.46
7.50
26%
6.34
8.04
-21%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
387
366
361
360
400
266
210
195
188
177
124
Net Sales Growth
9%
2%
0%
-10%
50%
26%
8%
4%
6%
42%
 
Cost Of Goods Sold
189
136
156
203
255
161
124
114
112
106
62
Gross Profit
198
231
204
157
146
105
87
81
76
71
62
GP Margin
51%
63%
57%
44%
36%
39%
41%
41%
40%
40%
50%
Total Expenditure
319
299
308
314
360
240
190
179
174
167
113
Power & Fuel Cost
-
7
7
6
6
4
3
2
1
1
1
% Of Sales
-
2%
2%
2%
1%
2%
2%
1%
0%
0%
1%
Employee Cost
-
52
51
38
29
18
19
18
17
14
10
% Of Sales
-
14%
14%
10%
7%
7%
9%
9%
9%
8%
8%
Manufacturing Exp.
-
61
52
29
36
26
19
18
17
16
13
% Of Sales
-
17%
14%
8%
9%
10%
9%
9%
9%
9%
11%
General & Admin Exp.
-
21
18
15
20
19
15
13
13
8
14
% Of Sales
-
6%
5%
4%
5%
7%
7%
7%
7%
4%
11%
Selling & Distn. Exp.
-
20
21
20
10
9
8
13
14
22
13
% Of Sales
-
5%
6%
6%
3%
4%
4%
7%
7%
13%
10%
Miscellaneous Exp.
-
3
3
3
4
3
2
1
1
0
13
% Of Sales
-
1%
1%
1%
1%
1%
1%
1%
1%
0%
0%
EBITDA
68
67
52
47
41
26
20
15
14
10
11
EBITDA Margin
18%
18%
15%
13%
10%
10%
10%
8%
7%
5%
9%
Other Income
6
6
5
3
7
7
2
6
3
3
1
Interest
3
4
5
7
10
8
7
8
8
5
3
Depreciation
7
7
6
6
5
5
4
3
2
2
1
PBT
64
62
46
37
33
20
12
11
7
6
9
Tax
13
13
12
9
9
5
2
2
2
2
2
Tax Rate
20%
22%
25%
25%
28%
24%
16%
16%
30%
33%
29%
PAT
51
49
35
28
24
15
11
10
5
4
6
PAT before Minority Interest
51
49
35
28
24
15
10
10
5
4
6
Minority Interest
0
0
0
0
0
0
0
0
0
0
0
PAT Margin
13%
13%
10%
8%
6%
6%
5%
5%
3%
2%
5%
PAT Growth
8%
41%
23%
19%
58%
41%
10%
89%
23%
-32%
 
EPS
25.50
24.36
17.31
14.06
11.84
7.51
5.33
4.83
2.56
2.09
3.05

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
269
224
192
141
111
99
89
81
77
53
Share Capital
20
20
20
16
16
16
16
16
16
11
Total Reserves
249
204
172
117
95
82
73
64
60
42
Non-Current Liabilities
28
25
32
34
33
26
25
22
11
30
Secured Loans
2
7
12
24
15
16
14
12
3
26
Unsecured Loans
0
0
0
0
10
3
3
2
2
2
Long Term Provisions
17
7
10
0
0
0
0
0
0
0
Current Liabilities
100
113
99
100
114
131
118
105
77
28
Trade Payables
43
43
32
30
45
67
48
42
23
18
Other Current Liabilities
11
11
13
15
12
14
16
16
12
4
Short Term Borrowings
30
49
45
53
51
48
55
47
40
0
Short Term Provisions
15
10
9
2
7
2
0
0
2
6
Total Liabilities
398
363
324
275
262
260
237
212
165
111
Net Block
121
117
103
98
66
65
65
38
28
21
Gross Block
138
128
108
121
88
82
79
49
37
28
Accumulated Depreciation
17
11
5
22
22
17
14
11
9
7
Non Current Assets
162
136
134
128
81
111
114
91
45
22
Capital Work in Progress
2
0
7
3
3
2
2
14
4
1
Non Current Investment
0
0
0
0
0
0
0
0
0
0
Long Term Loans & Adv.
38
19
24
27
12
43
46
39
13
0
Other Non Current Assets
0
0
0
0
0
0
0
0
0
0
Current Assets
236
227
190
147
181
149
123
122
120
89
Current Investments
18
11
10
0
0
0
0
0
0
0
Inventories
36
45
37
27
22
24
19
21
26
23
Sundry Debtors
122
109
91
81
119
89
75
65
40
31
Cash & Bank
8
15
12
13
12
10
15
17
13
13
Other Current Assets
52
1
1
0
29
26
14
18
41
21
Short Term Loans & Adv.
50
45
39
26
29
26
14
18
41
21
Net Current Assets
136
113
90
47
67
18
5
17
43
61
Total Assets
398
363
324
275
262
260
237
212
165
111

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
53
27
25
45
25
5
-16
12
-34
-11
PBT
62
46
37
33
20
12
10
5
8
9
Adjustment
9
12
11
14
11
13
9
14
7
1
Changes in Working Capital
-1
-22
-13
5
-2
-18
-32
-6
-48
-18
Cash after chg. in Working capital
70
36
35
52
28
7
-14
13
-33
-8
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-18
-9
-10
-7
-3
-3
-2
-1
-2
-2
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-18
-12
-25
-42
7
1
-16
-27
-11
-6
Net Fixed Assets
-12
-12
4
-29
-4
-1
-3
-5
-12
-6
Net Investments
-7
-3
-16
-7
-1
0
0
-11
0
0
Others
0
3
-14
-5
12
2
-13
-11
1
0
Cash from Financing Activity
-36
-11
0
-3
-32
-11
29
16
45
25
Net Cash Inflow / Outflow
-1
3
0
0
-1
-4
-3
1
0
9
Opening Cash & Equivalents
7
3
3
4
5
9
12
12
12
5
Closing Cash & Equivalent
5
7
3
3
4
5
9
12
12
13

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
135
112
96
82
68
61
55
50
47
47
ROA
13%
10%
9%
9%
6%
4%
4%
3%
3%
7%
ROE
20%
17%
17%
19%
14%
11%
11%
7%
6%
14%
ROCE
22%
19%
19%
21%
16%
11%
12%
11%
11%
17%
Fixed Asset Turnover
2.76
3.07
3.19
3.90
3.20
2.67
3.10
4.45
5.60
5.05
Receivable days
116
101
86
90
140
139
129
101
72
78
Inventory Days
41
42
32
22
31
37
37
45
50
54
Payable days
57
48
37
40
92
116
98
75
45
49
Cash Conversion Cycle
100
95
81
72
78
60
68
71
77
83
Total Debt/Equity
0.12
0.27
0.34
0.59
0.69
0.69
0.85
0.86
0.60
0.51
Interest Cover
17
10
7
4
3
3
2
2
2
4

News Update


  • Lincoln Pharmaceuticals gets European Union GMP's nod for Khatraj facility
    19th May 2020, 14:26 PM

    The certification will allow the company to market its products in all the 27 member countries of EU and also give access to European Economic Area countries

    Read More
  • Lincoln Pharmaceuticals gets nod to manufacture HCQ to fight COVID 19
    27th Apr 2020, 12:42 PM

    After necessary approval from DGFT company will be able to export these products

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.